A therapeutic agent for pulmonary hypertension, said therapeutic agent comprising an interleukin-5 receptor (IL-5R) inhibiting compound, and a therapeutic method therefor. More specifically, a therapeutic agent for pulmonary hypertension, said therapeutic agent comprising an antibody capable of specifically binding to the extracellular region of IL-5R or a fragment of the antibody, and a therapeutic method therefor.